Caris Life Sciences vs Natera
CAI and NTRA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and NTRA compare
Natera is the larger company, worth 7.4 times as much as Caris Life Sciences ($41.4B against $5.6B).
Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 37.8% for Natera).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −7.1% at Natera.
Natera scores higher on the StockData Score (10 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | NTRA |
|---|---|---|
| Size and price | ||
| Market cap | $5.6B | $41.4B |
| Share price | $19.94 | $287.47 |
| Change, 1 year | −16.4% | 40.7% |
| Change, 5 years | – | 204% |
| Beta (5Y) | 2.53 | 1.81 |
| Employees | 1,846 | 6,140 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.4× (better) | 15.3× |
| P/B | 8.8× (better) | 22.7× |
| EV/EBITDA | 36.5× | – |
| P/FCF | 195× (better) | 492× |
| FCF yield | 0.51% (better) | 0.20% |
| Fair value | $10.35 | $120.81 |
| Margin of safety | −92.6% (better) | −138% |
| Growth | ||
| Revenue growth (TTM) | 61.5% (better) | 37.8% |
| Revenue growth, 5Y average | – | 42.6% |
| Profitability | ||
| Operating margin | 13.4% (better) | −10.7% |
| Net margin | 9.2% (better) | −7.1% |
| FCF margin | 2.8% | 3.1% (better) |
| Return on equity | 17.2% (better) | −12.5% |
| Return on invested capital | 26.8% (better) | −40.8% |
| Financial health | ||
| Debt / equity | 0.61 | 0.04 (better) |
| Net debt / EBITDA | 1.79 | – |
| Interest coverage | 3.3× (better) | −75.9× |
| Current ratio | 6.71 (better) | 3.00 |
| Altman Z-score | 4.73 | 29.36 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.56% | – |
| Shareholder yield | 0.56% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 95.2% |
| Held by insiders | 64.1% | 3.9% |
| Insider net buying, 12 months | −$27.4M (better) | −$342M |
| Superinvestors holding | 2 | 3 (better) |
| Short interest, % of float | 11.3% | 4.4% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- NTRA stock overview
- NTRA income statement
- NTRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.